News and Press

Priv.-Doz. Dr. Martin Ludlow from the Research Center for Emerging Infections and Zoonoses at the University of Veterinary Medicine Foundation, Hannover, will hold a talk titled “Challenges and opportunities in the use of contemporary RSV-A and -B strains in the study of virus entry, spread, and immune responses” on October 28, 2026 at 3:00 pm in the Pharmacology Lecture Hall.

Dr. Mathilde Richard from the Department of Viroscience at Erasmus MC, Rotterdam, will give a lecture entitled “Mechanisms of highly pathogenic avian influenza virus emergence” on 29 October 2026 at 3.00 pm in the Pharmacology Lecture Hall.

From 1 October 2026, the Institute of Virology Innsbruck is switching to a new laboratory information system (LIS). Brief delays in result transmission may occur during the introductory phase.

The EU has approved Clesrovimab (Enflonsia®), a third RSV prophylactic antibody alongside Palivizumab and Nirsevimab — offering a fixed 105 mg dose regardless of an infant’s body weight. Clinical trials show efficacy and safety comparable to existing RSV antibodies, with a single dose covering a full RSV season.

The Institute of Virology Innsbruck has been accepted into the Global Virus Network (GVN) as a Center of Excellence — the first institution in Austria to receive this designation. The GVN is an international coalition of more than 90 centers across over 40 countries working on virological research, training and pandemic preparedness.